- Delic has positioned itself as a leading psychedelic wellness platform, with businesses spanning all corners within the sector
- Delic’s latest announced acquisition will make it the largest chain of operating psychedelic wellness clinics in the US
- The psychedelic wellness sector has enjoyed robust growth as of late, following the FDA’s move towards granting psilocybin “breakthrough therapy” status in 2018
- Denver and Oakland have been among the first US cities to decriminalize the use of psilocybin mushrooms with California currently studying whether to follow suit
- The psychedelic drugs market is expected to reach a size of $10.75 billion by 2027
When Michael Pollard embarked on writing his seminal book, How to Change Your Mind in 2018, the psychedelic wellness industry was a far different world to what we know today (https://ibn.fm/SiWdt). Although the psychedelic industry boasts a long history in America dating back to the 1950s, it’s only in the last few years that scientific research into the world of psychedelics and its related compounds has uncovered their potential to relieve a wide array of mental suffering, including depression, anxiety, and addiction. Delic Holdings (CSE: DELC) (OTCQB: DELCF) has sought to capitalize on the ongoing transformation within the sector, positioning itself as the leading psychedelic wellness platform committed to bringing science-backed benefits to all and reframing the psychedelic conversation.
Originally formed in 2019 to address the growing interest within the science-backed psychedelic wellness sector, Delic has transformed itself into a sprawling conglomerate with services spanning all areas within the sector. The company’s related businesses now include trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers and Ketamine Wellness Centers (pending acquisition), making it the largest psychedelic wellness clinic chain in the country.
According to the National Institute of Mental Health, over 17 million Americans have at least one major depressive episode every year, and up to 30 percent of them receive insufficient help from current medical treatments. Meanwhile, a further estimated 40 million adults struggle with anxiety disorders. In a move towards addressing the growing health crisis in 2018, the FDA moved towards granting psilocybin “breakthrough therapy” status for the treatment of severe depression. Shortly thereafter, first Denver and then Oakland voted to decriminalize the use of psilocybin mushrooms, with the state of California currently reviewing a bill to decriminalize a wide variety of psychedelics (https://ibn.fm/SV0LT).
With the sector on the cusp of broad-based legalization, the psychedelic drugs market is now projected to grow to a size of $10.75 billion by 2027, up from $4.75 billion in 2020 with a forecast CAGR of 12.36 percent over the period of 2021-2027 (https://ibn.fm/sqQwO).
Delic has responded by servicing the growing interest within the sector through the expansion of its wide-ranging media business, which includes the provision of a free education platform; hosting Meet Delic, the first-ever psychedelic wellness summit; and the creation of Delic Radio — a station featuring over 43 podcast episodes delving into different aspects of the psychedelic industry.
Simultaneously and in line with their goal of enabling billions of people to live happier lives through the provision of psychedelic treatments, Delic has acquired Ketamine Infusion Centers, which operates two ketamine clinics located in Bakersfield, California, and Phoenix, Arizona, and recently announced its acquisition of Ketamine Wellness Centers, which currently operates 10 clinics across Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas and Washington. Delic expects to open 15 additional clinics across the country over the next 18 months.
In recognition of the rapidly changing state of the industry, Delic has also focused its efforts around Delic Labs, a licensed cannabis and psilocybin research laboratory. It is the only Health Canada-licensed entity to exclusively focus on research and development of psilocybin vaporization technology.
The psychedelic wellness industry has long been recognized as one of the fastest growing segments within the global healthcare industry. With its business spanning all aspects of the sector, Delic looks optimally positioned to benefit from the continued growth in the sector and the ongoing legalization efforts around the world.
For more information, visit the company’s website at www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
